Loading
ENDRA Life Sciences Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Sept 2024.
ENDRA Life Sciences Inc.: what insiders have been doing
Every trade that managers of ENDRA Life Sciences Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 8 filings came from 6 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
With 8 filings in twelve months, the company is quieter than the median of 19 filings across the 5,816 companies we follow on the same exchange. Over the whole record (from 2021), the tally stands at 12 purchases and 1 sale.
Over the last twelve months, not one insider purchase of ENDRA Life Sciences Inc. stock was filed. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
26
Thresholds
n/a
Buy Volume
€162,633
12 ops. · all time
Sell Volume
€69,940
1 ops. · all time
Since the insiders bought
- -68.5%Entry US$7,770.00 · Close at T+365 US$2,450.00
- -66.0%Entry US$7,770.00 · Close at T+365 US$2,642.50
- -68.9%Entry US$8,050.00 · Close at T+365 US$2,502.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.04
Analyst consensus
1 analysts1.00/5
US$25.00Target US$25.00(+396%)US$25.00
Income statement
EBITDA-US$5.6M
Net income-US$7M0.0% margin
Valuation
PER (forward)-1.7x
P/Book1.2x
Beta-0.08
Balance sheet & cash
Market capUS$7.6M
Total debtUS$492.4k
Free Cash Flow-US$8.2M
Debt / Equity7%
Profitability & ownership
ROE-152.0%
ROA-77.3%
% insiders18.0%
% institutions18.0%
Last declaration on 25 June 2026
Declarations26 total
70,822 shares@ US$6.0017.63% mcap100.0% of flowCommonSEC144:0001213900-26-072178
26,921 shares0Common StockSEC:0001193125-26-092253:0
13,461 shares0Common StockSEC:0001193125-26-092251:0
60,324 shares0Common StockSEC:0001193125-26-021415:0
60,324 shares0Common StockSEC:0001193125-26-021414:0
20,000 shares0Common StockSEC:0001193125-26-021413:0
60,324 shares0Common StockSEC:0001193125-26-021412:0
75,000 shares0Common StockSEC:0001193125-26-021411:0
70,822 shares@ US$7.0682.6% of flowCommon StockSEC:0001193125-25-240662:0
5,384 shares0Common StockSEC:0000950170-25-091888:0
5,384 shares0Common StockSEC:0000950170-25-091887:0
5,384 shares0Common StockSEC:0000950170-25-091885:0
00Common StockSEC:0001610520-24-000153:0
Canonical exit: 25 Nov 2024 (T+90)
3,715 shares@ US$0.5523100.0% of flowCommon StockSEC:0001610520-24-000151:0
Canonical exit: 25 Nov 2024 (T+90)
15,000 shares@ US$1.6553.0% of flowCommon StockSEC:0001209191-23-031298:0
Canonical exit: 16 Aug 2023 (T+90)
83,333 shares@ US$1.2017.4% of flowCommon StockSEC:0001209191-23-026925:0
Canonical exit: 31 Jul 2023 (T+90)
1,500 shares@ US$3.4011.1% of flowCommon StockSEC:0001209191-22-060895:0
Canonical exit: 9 Mar 2023 (T+90)
10,000 shares@ US$0.176.4% of flowCommon StockSEC:0001209191-22-058875:0
Canonical exit: 21 Feb 2023 (T+90)
20,000 shares@ US$0.2712.5% of flowCommon StockSEC:0001209191-22-047298:0
Canonical exit: 20 Nov 2022 (T+90)
20,000 shares@ US$0.2620.4% of flowCommon StockSEC:0001209191-22-047297:0
Canonical exit: 20 Nov 2022 (T+90)
25,000 shares@ US$0.2111.3% of flowCommon StockSEC:0001209191-22-032746:0
Canonical exit: 24 Aug 2022 (T+90)
25,000 shares@ US$0.2212.1% of flowCommon StockSEC:0001209191-22-031319:0
Canonical exit: 16 Aug 2022 (T+90)
5,100 shares@ US$0.19100.0% of flowCommon StockSEC:0001209191-22-030307:0
Canonical exit: 15 Aug 2022 (T+90)
100,000 shares@ US$0.196373.2% of flowCommon StockSEC:0001209191-22-029593:0
Canonical exit: 14 Aug 2022 (T+90)
22,815 shares0Common StockSEC:0001209191-21-057234:0
25 of 26 declarations
About ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc. is a U.S.-based medical technology company listed on Nasdaq (United States), focused on biomarker imaging and non-invasive solutions for assessing liver and tissue fat content. The company is centered on its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS®) platform, which combines thermo-acoustic and ultrasound principles to measure tissue fat, with its primary commercial and clinical focus on liver fat quantification. ENDRA is headquartered in Ann Arbor, Michigan, and its market position is that of a niche, pre-commercial challenger targeting a very large but still underserved global diagnostic need. ([nasdaq.com](https://www.nasdaq.com/press-release/endra-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and?utm_source=openai))
From a historical perspective, ENDRA built its capabilities around imaging and tissue measurement technologies before narrowing its strategic emphasis to the early detection and monitoring of steatotic liver disease, including MASLD and MASH. That shift is important from an equity research perspective because it moves the company toward a high-unmet-need clinical area where better diagnostics could have meaningful adoption if performance, reimbursement, and regulatory requirements are met. In 2025, ENDRA also disclosed an expanded business strategy that includes a digital asset treasury initiative, which adds a less conventional financial layer to its corporate profile and increases the complexity of the investment case. ([nasdaq.com](https://www.nasdaq.com/press-release/endra-life-sciences-provides-business-update-and-reports-first-quarter-2025-financial?utm_source=openai))
Read moreShow less
The core product story remains TAEUS®, particularly TAEUS Liver, which is being developed to quantify liver fat at the point of care and, in some applications, to support monitoring during minimally invasive ablation procedures. Recent company updates have highlighted feasibility-study and pilot-study results indicating progress in accuracy, repeatability, and alignment with MRI-based benchmarks. For investors, this suggests technical momentum, but not yet a fully de-risked commercialization path. The key watchpoints are still clinical validation, regulatory clearance, and the ability to prove a practical workflow advantage versus established imaging modalities. ([businesswire.com](https://www.businesswire.com/news/home/20250616575045/en/ENDRAs-Ongoing-Multisite-Pilot-Study-Reveals-Important-Enhancements-to-Boost-TAEUS-Liver-Accuracy-and-Repeatability-Against-MRI-Gold-Standard?utm_source=openai))
Competitively, ENDRA operates in a field dominated by larger, better-capitalized medical imaging and diagnostic players. Its potential advantage is an easier, lower-cost, point-of-care approach that could improve access compared with more resource-intensive reference methods. However, ENDRA’s small-cap status also means elevated execution risk: the company has been managing tight liquidity, has raised capital through private placements, and has continued to rely on external financing while pursuing product and clinical milestones. Public filings and corporate updates in 2025 and 2026 also point to ongoing strategic review activity by the board, underscoring the company’s focus on maximizing shareholder value. ([businesswire.com](https://www.businesswire.com/news/home/20251117008793/en/ENDRA-Life-Sciences-Recaps-Major-Milestones-and-New-Strategic-Initiatives-Announces-Third-Quarter-2025-Financial-Results?utm_source=openai))
Geographically, ENDRA is a U.S. company with headquarters in Michigan, but its target market is global if the technology ultimately achieves broader regulatory and commercial acceptance. In short, ENDRA Life Sciences is a Nasdaq-listed U.S. health-tech micro-cap with a differentiated diagnostic platform, meaningful long-term upside if development succeeds, and substantial financing and commercialization risk in the near term. ([nasdaq.com](https://www.nasdaq.com/press-release/endra-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
